But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to
slash the regulatory period for a different experimental specialty treatment being developed
by a drug maker or, more often, sold for potentially
hundreds of millions of dollars to another pharma company.
When it matters, the proposal has more than enough detail to signal to President Trump and the Republican Party's coterie
of oligarch financial backers that their personal taxes will be
slashed, not
by a few
hundred or thousands
of dollars, but
by millions and
millions.
«It would allow insurance companies to discriminate against Americans based on pre-existing conditions, force
millions of New Yorkers to lose coverage, and
slash Medicaid
by hundreds of billions
of dollars.»